韦里西瓜特改善了患有法布里病的男性患者的心脏功能和微循环:一个病例报告
Bingyang Zhou1, Ning Ren1, Jie Geng1
1Department of Cardiology, Tianjin Chest Hospital, Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Tianjin Municipal Science and Technology Bureau, Tianjin, China.
概括
法布里病 (FD) 是一种罕见的遗传疾病,可以导致严重的心脏问题,如心力衰竭. 这一案例突出了与FD相关的心力衰竭的成功治疗,使用输送器,改善心脏功能.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 罕见疾病 罕见疾病
背景情况:
- 费布里病 (FD) 是一种X链接的遗传性疾病,常常被误诊.
- FD可能导致显著的心血管并发症,包括心力衰竭和肺高血压.
- 早期诊断和适当的治疗对于改善患者的治疗结果至关重要.
研究的目的:
- 报告一个Fabry病病例,表现为心力衰竭和严重的肺动脉压力.
- 调查冠状动脉微血管功能障碍在FD相关心脏并发症中的作用.
- 为了评估 vericiguat在治疗患有法布里病的患者心力衰竭的疗效.
主要方法:
- 一个69岁的男性患有法布里病的病例报告.
- 诊断评估包括心声回声,基因分析 (GLA c.215T>C p.Met72Thr突变) 和单光子发射计算断层扫描 (SPECT).
- 治疗涉及标准的心力衰竭药物,包括输送器.
主要成果:
- 该患者出现了复发性心房动,心力衰竭和明显升高的肺动脉压力.
- 基因分析证实了GLA c.215T>C p.Met72Thr突变,表明了法布里病.
- SPECT检测显示了冠状动脉微血管功能障碍.
- 用输血管治疗导致心脏功能和微血管输液显著改善.
结论:
- 费布里病可以表现为严重的心脏干扰,包括心力衰竭和肺高血压.
- 冠状动脉微血管功能障碍是FD相关心脏病理学的关键特征.
- 维里西瓜特可能为患有法布里病的患者治疗心力衰竭提供有益的治疗选择.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337